Prognostic significance of follicular lymphoma international prognostic index (FLIPI) and FLIPI2 in follicular lymphoma patients treated with rituximab plus chemotherapy
10.3760/cma.j.issn.1009-9921.2013.12.005
- VernacularTitle:两种滤泡性淋巴瘤国际预后指数对利妥昔单抗联合化疗治疗滤泡性淋巴瘤的预后意义
- Author:
Pengpeng XU
;
Dong YU
;
Ying QIAN
;
Qiusheng CHEN
;
Xiao GU
;
Li ZHANG
;
Weili ZHAO
- Publication Type:Journal Article
- Keywords:
Lymphoma,follicular;
Follicular lymphoma international prognostic index;
Rituximab
- From:
Journal of Leukemia & Lymphoma
2013;22(12):720-723
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the prognostic significance of follicular lymphoma international prognostic index (FLIPI) and FLIPI2 in Chinese FL patients for better prognostic model.Methods 63 newly diagnosed FL patients who received rituximab plus CHOP (cyclophosphamide,doxorubicin,vincristine and prednisone)-like chemotherapy from January 2003 to December 2010 were retrospectively analyzed according to FLIPI and FLIPI2 scoring system.Results According to FLIPI,31 patients (49.2 ％) were stratified into the low risk group (0-1 point),24 (38.1％) into the intermediate risk group (2 points),and 8 (12.7 ％) into the high risk group (3-5 points).As for FLIPI2 scoring,17 cases (27.0 ％) were classified in low risk group (0 point),42 cases (68.3 ％) in intermediate risk group (1-2 points),and 4 cases in high risk group (3-5 points).The overall response rates and 2-year progression free survival (PFS) rates of the three risk groups were 93.5 ％ (29/31),91.7 ％ (22/24),75.0 ％ (6/8) (P =0.27),and 85.7 ％,75.2 ％,58.8 ％ (Log-rank =1.063,P =0.59) respectively in FLIPI.In terms of FLIPI2,the overall response rates and 2-year PFS rates of the three groups were 100.0 ％ (17/17),90.7 ％ (39/42),50.0 ％ (2/4) (P =0.01) and 92.9 ％,74.0 ％,33.3 ％ (Log-rank =7.075,P =0.03).Conclusion FLIPI2 presents more robust prognostic significance than FLIPI in disease progression perspective for FL patients treated with R-CHOP like regimens in this study.
